GlassScriptPhysician profile
Morgan Unser
NPI 1427833722
$9,436.25
in general payments reported to CMS, 2019-2025
28 companies · $4,215 in 2025
The $4,215 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.50 · 2023: $789 · 2024: $4,408 · 2025: $4,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,376 · Education: $35.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,376.14 |
| Education | $35.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,308.06 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $951.47 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $948.19 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $794.75 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $730.53 | 2024-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $670.85 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $538.40 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $527.05 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $377.14 | 2024-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Corium, LLC | $350.91 | 2024-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $268.05 | 2024-2025 | Quviviq, Quviviq |
| E.R. Squibb & Sons, L.L.C. | $212.26 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $208.05 | 2024-2025 | Trintellix |
| Lundbeck LLC | $207.98 | 2023-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $162.24 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $130.20 | 2023 | |
| Boston Scientific Corporation | $129.19 | 2025 | Embold Fibered |
| Gilead Sciences, INC. | $125.00 | 2024 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.00 | 2023 | Xifaxan |
| Noven Therapeutics, LLC | $113.26 | 2024 | Xelstrym |
| Biogen, INC. | $111.21 | 2025 | Zurzuvae |
| Jazz Pharmaceuticals INC. | $110.53 | 2024 | |
| Supernus Pharmaceuticals, INC. | $109.44 | 2024-2025 | Qelbree |
| Itamar Medical INC | $103.80 | 2023 | Watchpatone |
| Sage Therapeutics, LLC | $43.87 | 2025 | Zurzuvae |
| Indivior INC. | $39.58 | 2024 | Perseris |
| Collegium Pharmaceutical, INC. | $21.06 | 2025 | Jornay Pm |
| Noven Pharmaceuticals, INC. | $18.18 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Unser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.